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Abstract: It is increasingly recognised that lncRNAs play essential regulatory roles in 
fundamental biological processes and, consequently, that their dysregulation may contribute 
to major human diseases, including cancer. Better understanding of lncRNA biology may 
therefore offer new insights into pathogenetic mechanisms and thereby offer novel 
opportunities for diagnosis and therapy. Of particular interest in this regard is GAS5 
lncRNA, which is down-regulated in multiple cancers, with expression levels related to both 
clinico-pathological characteristics and patient prognosis. Functional studies have further 
shown that GAS5 lncRNA both inhibits the proliferation and promotes the apoptosis of 
multiple cell types, and that together these cellular mechanisms of action are likely to form 
the basis of its tumour suppressor action. At the same time, advances have been made in our 
understanding of the molecular mechanisms of GAS5 lncRNA action in recent years, 
including riborepression of certain steroid hormone receptors and sequestration of miR-21, 
impacting key regulatory pathways of cell survival. Overall this accumulating knowledge 
has the potential to improve both the diagnosis and treatment of cancer, and ultimately 
patient outcome. 
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1. Introduction 
The long non-coding RNAs (lncRNAs) are a major component of the human transcriptome, but many 
remain to be functionally annotated [1,2]. Nevertheless, regulatory roles in fundamental cellular 
processes have emerged for a number of these molecules in recent years, and it is increasingly recognised 
that major pathologies, such as cancer, are characterized by dysregulated expression of lncRNAs [1–4]. 
Indeed, it is now widely acknowledged that lncRNAs are likely to be of crucial importance in the 
pathogenesis of cancer; therefore, increased understanding of lncRNA biology may lead to novel and 
better approaches for the diagnosis and treatment of this important disease. 
To illustrate these points, this review focusses on the relatively well characterized lncRNA, GAS5, 
and cancer. This lncRNA is a transcript of the growth arrest-specific 5 (GAS5) gene, a non-protein 
coding gene, which was first isolated in 1988 in a search for novel tumour suppressors by subtractive 
cDNA cloning of genes which are preferentially expressed in growth-arrested cells [5]. As will be discussed 
here, more recent work has shown that GAS5 lncRNA is dysregulated in multiple cancers and confirm 
a tumour suppressor role for this molecule. Recent advances in our understanding of the cellular and 
molecular mechanisms of GAS5 lncRNA action will then be considered, before discussing how this 
knowledge may be harnessed clinically in the future for the improved diagnosis and treatment of cancer. 
2. Gene Structure 
GAS5 is localized at 1q25.1 and encodes small nucleolar RNAs (snoRNAs), microRNAs (miRNAs) 
and PIWI-interacting RNAs (piRNAs), in addition to lncRNA [6–8]. The gene comprises 12 exons, 
which contain only a short open reading frame and are not thought to encode a functional protein; rather 
these exons are spliced to yield two possible mature lncRNAs, termed GAS5a and GAS5b, due to the 
presence of alternative 5'-splice donor sites in exon 7 (Figure 1) [6]. GAS5 additionally encodes within 
its introns ten (human) or nine (mouse) box C/D snoRNAs, which participate in the 2'-O-methylation of 
rRNA; the U44 snoRNA serves as a guide to modify 18S rRNA, whereas the remaining snoRNAs all 
direct the modification of 28S rRNA [6]. Moreover, at least three of these snoRNAs—U44, U74 and 
U78—may give rise to miRNAs [7]. A 5'-terminal oligopyrimidine (5'-TOP) tract is present in exon 1 
of GAS5 [6]; this motif is commonly found in genes that encode proteins that function in ribosome 
biogenesis and translation. While the 5'-TOP sequence usually serves to control the translation of such 
proteins, in the case of GAS5, it serves to control transcript levels (see Section 4). 
The processing of the GAS5 is poorly understood but is likely to be complex, insofar as a multitude 
(29 at the latest count) of transcripts have been described [9]. Many of these contain retained introns  
and may exert isoform-specific functional effects [10,11]. Nevertheless, in our experience, mature 
lncRNA appears to be the predominant transcript in most cell lines, and particularly the GAS5b variant 
(Figure 1). Notably there is partial overlap of 40 or so of the 3' terminal nucleotides of GAS5 with 
another non-protein coding gene, GAS5-antisense-1 (GAS5-AS1), which is encoded on the opposite 
strand and arranged tail-to-tail with GAS5 (Figure 1). GAS5-AS1 is largely uncharacterized and the 
impact of its transcription on GAS5 expression is unknown. 
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Figure 1. Genomic context, gene structure and selected products of the human GAS5 gene. 
For genomic context, HUGO Gene Nomenclature Committee (HGNC) approved gene 
symbols are used, with the corresponding HGNC identity number given below each symbol. 
Exon/intron structure is based on published data [6]; note the presence of two alternative  
5′-splice donor sites in exon 7. The two possible resulting mature lncRNAs are termed 
GAS5b (contains exon 7b and corresponds to the GAS5 reference sequence, NR_002578.2) 
and GAS5a (contains exon 7a); the latter is predicted to be 39 bases shorter than GAS5a 
(based on [6] and GenBank: AF141346.1). The additional GAS5 expressed sequence tags 
(ESTs) shown here have all been reported to induce growth arrest in lymphoid cell lines [10]. 
3. Protein-Coding or Non-Protein Coding? 
Recent studies have reported that certain lncRNAs give rise to small polypeptides or  
micropeptides [12,13]. Indeed, in the case of GAS5 lncRNA, this has been recognized for several years [6]. 
Thus, human GAS5 may encode a 50 amino acid polypeptide whereas, for mouse and rat GAS5,  
23 and 13 amino acid polypeptides, respectively, have been predicted [6,14,15]. With the exception of 
the 5'-TOP sequence and snoRNA-encoding intronic sequence, GAS5 sequence has generally been 
thought to be poorly conserved between humans and rodents and even between rats and mice [6,14,15], 
albeit it is now recognized that discrete, functionally important portions of lncRNA sequence show 
greater conservation than previously appreciated [16]. Notably, frameshift mutation of the longest open  
reading frame (ORF) in GAS5 occurs naturally in several inbred mice strains, but has no obvious 
deleterious phenotypic effects despite predicted marked disruption of polypeptide sequence [17], further 
arguing against any significant biological role for GAS5-encoded protein. Moreover, antibodies raised 
against in vitro translated mouse GAS5 lncRNA fail to detect any protein in cultured cells or in murine 
tissues [14], perhaps indicating that the polypeptide is expressed at very low levels or actively degraded. 
In conclusion, based on current evidence, GAS5 is unlikely to encode a functionally important 
polypeptide; rather its translation plays an integral role in the regulation of transcript levels, as will be 
discussed in the next section. 
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4. Regulation of GAS5 Expression 
Post-transcriptional mechanisms underlie the increase in GAS5 expression that accompanies growth 
arrest due to saturating cell density or nutrient deprivation, whereas transcriptional mechanisms may 
control GAS5 expression in differentiating cells [14,18]. The former is perhaps best understood and 
involves interplay between the mammalian target of rapamycin (mTOR) and nonsense-mediated decay 
(NMD) pathways [6,19]. Under conditions in which mTOR activity is high, such as in actively growing 
cells, GAS5 translation is promoted due to the presence of the 5'-TOP sequence. However due to the 
short ORF and the presence of multiple termination codons in its sequence, this results in degradation of 
transcripts via NMD and a lowering of their levels (Figure 2). Conversely, when mTOR activity is low, 
such as in growth-arrested cells, GAS5 transcripts are no longer translated and this in turn, prevents NMD 
(which only occurs for actively translated transcripts), resulting in the accumulation of GAS5 transcripts 
(Figure 2). 
 
Figure 2. Interplay between mammalian target of rapamycin (mTOR) and nonsense-
mediated decay (NMD) regulates cellular GAS5 lncRNA levels. 
5. GAS5 Expression in Health and Disease 
GAS5 is expressed in the mouse preimplantation embryo from at least the 8-cell stage, with lower 
abundance at the morula and blastocyst stages [20]. From 8 days post-conception, a spatio-temporal 
pattern of expression is observed [14]; expression is particularly high in the neural tube in the early 
embryo and in certain brain structures such as the forebrain and hypothalamus in mid-late gestation. 
Northern blots of adult tissue revealed relatively high GAS5 levels in brain but low levels in spleen and 
liver, suggesting an inverse relationship between expression levels and tissue replicative rate [14]. 
Disturbed GAS5 expression has been reported in a range of animal pathological models including 
malformations of neural tube closure [21,22], neuronal hypoxia [23] and the autoimmune disease, 
systemic lupus erythematosus [24]. More notable however, is the large body of evidence linking GAS5 
dysregulation to a wide array of human cancers (Table 1). 
GAS5 expression is typically reduced in such cancers and clinico-pathological characteristics, such 
as tumour size, staging, invasion and/or regional lymph node metastasis, show disease-specific inverse 
correlations with GAS5 levels (Table 1). Cell lines of affected cancers also tend to display reduced GAS5 
expression, especially models of advanced disease (Table 1). Moreover, forced expression of GAS5 
lncRNA in such cells inhibits tumour growth in xenograft models (Table 1), mirroring clinical findings. 
Notably, in an LNCaP xenograft model, GAS5 levels decline concomitant with the acquisition of 
castrate-resistance, which has important implications for the treatment of advanced prostate cancer. 
More crucially, for many cancers, low GAS5 lncRNA levels are predictive of poor prognosis (Table 1). 
Together, these findings support a tumour suppressor role for GAS5 lncRNA in vivo. 
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Table 1. GAS5 expression in human cancer. ↓ and ↑ = down- and up-regulated expression, 
respectively, in the indicated cancer tissues/model systems; → = leading to; TNM = cancer 
staging system of the International Union for Cancer Control (UICC) which takes into account 
the primary tumour (T), lymph nodes (N) and metastases (M)—a higher stage indicates a 
more advanced cancer; FIGO = comparable staging system of the International Federation 
of Gynecologists and Obstetricians (FIGO) for cancers of the female reproductive organs. 
Cancer Comments Reference 
Breast 
↓ Patient tissue/cell lines; poor patient survival 
GAS5 inhibits xenograft tumour growth 
[11,25,26] 
Prostate ↓ Xenografts as cells acquire castrate-resistance [27] 
Head/neck 
squamous cell 
↓ Patient tissue; poor patient survival [25] 
Glioblastoma 
multiforme 
↓ Patient tissue; poor patient survival [25,28] 
Renal clear cell ↓ Patient tissue/cell lines [29] 
Bladder ↓ Patient tissue/cell lines [30] 
Hepatocellular 
↓ Patient tissue → increased tumour size/clinical stage/lymph node 
spread; poor patient survival 
[31] 
Pancreatic ↓ Patient tissue/cell lines [32] 
Non small cell lung 
↓ Patient tissue/cell lines → increased tumour size/TNM stage  
GAS5 inhibits xenograft tumour growth 
[33,34] 
Mesothelioma ↑ Patient tissue; ↓ Cell lines [35] 
Gastric 
↓ Patient tissue/cell lines → increased tumour size/TNM 
stage/invasion/regional lymph nodes; poor patient survival  
GAS5 inhibits xenograft tumour growth 
[36,37] 
Colorectal 
↓ Patient tissue → increased tumour size/TNM stage; lower grade; poor 
patient survival 
[38] 
Cervical 
↓ Patient tissue → increased FIGO stage/lymph node spread/vascular 
invasion; poor patient survival 
[39] 
Adrenocortical ↓ Patient tissue; unrelated to recurrence [40] 
Multiple myeloma ↓ Patient plasma [41] 
Solid tumours apart, GAS5 is also down-regulated in multiple myeloma neoplasms of B-cells but its 
expression is unaffected in chronic lymphocytic leukemia [41]. In a patient with diffuse large B-cell 
lymphoma, a chromosomal translocation affecting GAS5, t(1;3)(q25;q27), has been described [42]. One 
breakpoint occurs within the U76 snoRNA sequence and results in a chimeric transcript in which GAS5 
5'-TOP to exon 3 sequence is spliced to BCL6 exon 2. Since the fusion transcript contains the ORF of 
BCL6, then it would not be targeted for NMD, unlike GAS5 lncRNA. Consistent with this finding, GAS5 
was recently identified using a genome-wide strategy as one of several genes that are susceptible to 
activation-induced cytidine deaminase-mediated rearrangement in murine B-lymphocytes [43]. In addition, 
chromosomal translocations that produce oncogenic tyrosine kinases may themselves impact upon GAS5 
expression, insofar as GAS5 lncRNA levels are suppressed by BCR-ABL but induced by TEL-JAK2 in 
murine lymphoid cells [44]. 
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When considering the importance of GAS5 lncRNA in relation to oncogenesis, an important issue 
to address is the mechanism of the down-regulation that occurs across many cancers, especially since 
GAS5 expression inversely correlates with rates of cell proliferation, which themselves tend to be 
higher in many cancers. In this regard, two recent studies suggest that epigenetic silencing may be 
responsible in colorectal and NSCLC cell lines, involving hypermethylation of CpG islands in the 
GAS5 promoter [33,45]. Moreover, functional studies support a more direct tumour suppressor role 
for GAS5 lncRNA, as will be discussed in detail in the next section. 
6. Functional Activities of GAS5 lncRNA 
Clearly GAS5 lncRNA negatively regulates the growth of cell line and xenograft models of various 
cancers (Table 1). Studies in the latter systems, as well as in untransformed primary cells, demonstrate 
that GAS5 exerts complementary effects on cell proliferation (inhibitory) and apoptosis (stimulatory), 
and together these are likely to form the main basis of its tumour suppressor activity in vivo. Additional 
mechanisms centering on cell migration/invasion may also contribute to certain cancers, since GAS5 
lncRNA has been recently reported to negatively regulate the migration of renal cell and cervical 
carcinoma cell lines [29,39], whereas it has no effect on the migration of NSCLC cells [33]. However, 
the molecular basis of these findings remains to be elucidated. The cellular processes of relevance to 
cancer that are regulated by GAS5 lncRNA, along with possible downstream molecular targets are 
summarized in a simplified scheme (Figure 3), which will now be discussed in further detail. 
 
Figure 3. Summary of biological processes that are regulated by GAS5 lncRNA, including 
possible downstream molecular targets. ↓ and ↑ = down- and up-regulation, respectively. 
6.1. Regulation of Cell Proliferation 
As mentioned at the outset, GAS5 was originally identified in a screen for novel genes involved in 
growth arrest [5]. Indeed, subsequent work using plasmid constructs and siRNA-mediated silencing 
approaches in human T-cell lines and normal lymphocytes, has demonstrated that GAS5 lncRNA per se 
is both necessary and sufficient for growth arrest [10]; similar observations have also been reported for 
a wide range of human epithelial cell lines [29,30,32,33,36,39]. In many cell types, GAS5 lncRNA 
arrests cells in the G0/G1 phase of the cell cycle; conversely, GAS5 knockdown is associated with a 
shorter cell cycle length concomitant with a decreased proportion of cells in G0/G1 and an increased 
proportion of cells in S-phase relative to controls [10,29,30,32,33,35–38]. 
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Cyclin-dependent kinase 6 (CDK6), which promotes G1 progression and G1/S transition of the cell 
cycle, is a GAS5-associated protein in bladder cancer cells [30]. GAS5 silencing increases—and ectopic 
GAS5 lncRNA expression decreases—CDK6 mRNA and protein levels in cell lines [30,32]; a similar, 
inverse relationship between GAS5 and CDK6 levels has been reported in bladder and pancreatic cancer 
tissues [30,32], suggesting that this interaction is operative in vivo. Importantly, knockdown of CDK6 
expression in these cells blocks the stimulation of cell proliferation consequent upon GAS5 silencing; 
conversely, CDK6 overexpression mitigates cell proliferation inhibition by GAS5 lncRNA [30,32]. 
These effects are partial [30,32], suggestive of additional mechanisms of action of GAS5 in modulating 
the cell cycle. Indeed, with respect to GAS5 levels, an inverse relationship has been reported both for 
the cyclin D1 protein, which forms a complex with CDK4/CDK6 and activates these kinases, and for 
the transcription factor E2F1, which regulates the expression of key cell cycle regulatory genes, whereas a 
positive relationship exists for the cyclin-dependent kinase inhibitor, p21 [33,36]. In all these cases, 
regulation is post-transcriptional [33,36], but the underlying molecular mechanism(s) are unknown. 
Recently, Y-box binding protein 1 (YBX1), a transcriptional activator of p21, has been reported to 
interact with GAS5 lncRNA in stomach cancer cells [37]. This interaction partly depends on GAS5 exon 
12-derived sequence, results in negative regulation of YBX1 protein turnover, and is accompanied by 
changes in both mRNA and protein levels of p21 [37]. Like YBX1, the translation of another regulator 
of cell proliferation, c-Myc (which itself up-regulates cyclins and down-regulates p21), is negatively 
controlled by GAS5 lncRNA in lymphoma cells [46], as discussed later (see Section 7.3). The relative 
contribution of these various mechanisms to GAS5-mediated growth arrest remains to be addressed. 
6.2. Apoptosis Control 
The first suggestion that GAS5 may regulate apoptosis came from functional cloning experiments 
employing a mouse FDCP1 cDNA library and γ-irradiated mouse W7.2c thymoma cells to isolate novel 
regulators of cell survival. This resulted in the isolation of a partial GAS5 sequence which suppressed 
apoptosis [47]; subsequent experiments in this cell line and in a range of human cell lines/primary cells 
demonstrated that more complete GAS5 sequences actually promoted apoptosis [10,11]; mature GAS5 
lncRNA is sufficient for this activity [26,29,33,36,48–50]. 
While transfection of GAS5 lncRNA per se is sufficient to induce apoptosis in most human cell lines, 
an exception is the immortalized normal breast cell line, MCF10A [11]. In this cell line, GAS5 has no 
effect basally but enhances apoptosis consequent upon treatment with cell death-inducing stimuli [11] 
and, as such, GAS5 can be considered an apoptosis promoter. GAS5 lncRNA also enhances apoptosis 
induction by external stimuli in those cell lines which are responsive under basal conditions; these effects 
can be additive [11,48,49] or synergistic [34]. Potent pro-apoptotic activity has been observed for 
exogenous GAS5 lncRNA constructs in cells which exhibit marked reductions in endogenous GAS5 
expression, including for example triple-negative breast cancer and hormone-resistant prostate cancer 
cells [48,49], indicating that such cells retain GAS5 sensitivity. 
Nevertheless, the influence of reduced GAS5 expression in reducing cancer cell sensitivity to 
apoptosis is perhaps of greater clinical relevance, given the widespread down-regulation of GAS5 
expression that occurs across multiple cancer types. Silencing of GAS5 inhibits the basal apoptotic rate 
in certain cell lines, but this has negligible impact on culture survival overall, presumably because the 
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basal apoptotic rate tends to be low in most cell lines when grown under favorable conditions [48,49]. 
More strikingly, GAS5 silencing attenuates apoptosis induction by a wide range of stimuli, including 
chemotherapeutic agents with diverse mechanisms of action (Table 2), indicating that GAS5 lncRNA 
functions in a late and common step of activation of the apoptotic machinery by such agents. Not all 
treatments show dependence on GAS5 lncRNA for their action, insofar as imatinib-induced death of 
breast cancer cells is unaffected by GAS5 silencing [49], however the action of another tyrosine kinase 
inhibitor, gefitinib, shows GAS5-dependence in lung cancer cells [34]. Crucially, for several agents, 
quantitative relationships have been noted between GAS5 lncRNA levels and both the extent of apoptosis 
induction (direct relationship) and the associated loss of culture viability (inverse relationship) [34,48,49], 
suggesting a key role for GAS5 lncRNA in apoptosis control. 
Table 2. Apoptotic stimuli which require GAS5 lncRNA for their action. 
Treatment Model Reference 
DNA damage 
Ultraviolet-C irradiation 
Breast: MCF10A, MCF7, T47D & MDA-MB-231 cells 
Prostate: 22Rv1 cells 
Kidney: HEK293T cells 
[11,26,49]
[48] 
[11] 
Alkylating agent 
Cisplatin 
Breast: MCF10A, MCF7 cells 
Kidney: HEK293T cells 
[11] 
[11] 
Taxane 
Docetaxel 
Breast: MCF7 & T47D cells 
Prostate: 22Rv1 cells 
[49] 
[48] 
Anti-tumour antibiotic 
Doxorubicin 
Mitoxantrone 
Breast: MCF10A, MCF7 cells 
Prostate: 22Rv1 cells 
[11,26] 
[48] 
Antimetabolite 
5-Fluorouracil Breast: MCF7, T47D [49] 
Corticosteroid 
Dexamethasone Lymphoid: CEM-C7 [10] 
MDM2 antagonist 
Nutlin-3a Prostate: 22Rv1 cells [48] 
EGF-R inhibitor 
Gefitinib Lung: A549 cells & xenografts [34] 
mTOR inhibitor 
Rapamycin/rapalogues 
 
 
AZD8055, BEZ235 
Lymphoid: CEM-C7, MOLT4, Jeko-1 & Z-138 cells; 
primary T-lymphocytes 
Prostate: 22Rv1, LNCaP, PC3 & DU145 cells 
Prostate: 22Rv1, LNCaP, PC3 & DU145 cells 
[51,52] 
 
[53] 
[53] 
Similar quantitative relationships are characteristic of key apoptosis regulators, such as members of 
the Bcl-2 family, for which the balance between pro- and anti-apoptotic molecules determines overall 
sensitivity to apoptotic stimuli [54]. Although the influence of GAS5 lncRNA on Bcl-2 family members 
has not been studied to-date, several reports demonstrate that other important regulators of sensitivity to 
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apoptosis are targets for this lncRNA. Thus the expression of cIAP2, which is a member of the Inhibitor 
of Apoptosis Protein (IAP) family and a glucocorticoid–responsive gene, is subject to riborepression by 
GAS5 lncRNA (see Section 7.1) in some [50,55]—but not all [33]—cells. Furthermore, GAS5 lncRNA 
enhances the expression of the master regulator of apoptosis, p53, in the NSCLC cell line, A549, via an 
uncharacterised post-transcriptional mechanism [33]. However, GAS5 lncRNA can also induce 
apoptosis in p53-null NSCLC cells, demonstrating that there is not an absolute requirement for p53 for 
this activity [33]. 
7. Mechanisms of GAS5 lncRNA Action 
To-date three different molecular mechanisms of action have been described for GAS5 lncRNA.  
In the first two—and best understood—mechanisms, GAS5 lncRNA acts as decoy to either repress 
steroid receptor-induced transcriptional activation or to inhibit miR-21 action. These decoy activities are 
quite distinct, involving separate portions of GAS5 lncRNA sequence; to reflect this distinction, the 
terms “riborepression of steroid hormone receptor action” and “miRNA sponge” are used here. 
Additional mechanisms, involving direct interaction with CDK6, YBX1 or other proteins identified in 
interacting partner screens [30,37], for example, are feasible, but require further characterization and are 
not considered further here. 
7.1. Riborepression of Steroid Hormone Receptor Action 
A major breakthrough in our understanding of GAS5 lncRNA action came with the demonstration 
that it could directly interact with the DNA binding domain of the glucocorticoid receptor (GR) [50].  
This prevents receptor binding to glucocorticoid response elements (GRE) in target genes and 
consequently blocks the activation of target gene transcription [50]. Through its competition with GREs 
for binding the GR, GAS5 lncRNA is archetypically considered to act as a decoy molecule or riborepressor 
of steroid hormone receptor action [50]. 
Since glucocorticoid receptor-induced transcriptional activation essentially occurs within the nucleus, 
then riborepression also requires GAS5 lncRNA to be localized in this subcellular compartment; 
glucocorticoid is thought to enhance the association of cytoplasmic GAS5 lncRNA with the GR, 
resulting in its co-migration with the ligand-activated GR to the nucleus [50]. Once in the nucleus, it can 
then compete with DNA GREs located in target genes for the binding of the GR DNA binding domain; 
compared with DNA GREs, GAS5 lncRNA has ca. 2-fold higher binding affinity for the GR DNA 
binding domain and consequently, stronger displacing activity [50]. A wide range of glucocorticoid-
responsive genes which contain GREs in their promoters are subject to such transcriptional repression 
by GAS5 lncRNA, which notably include negative regulators of apoptosis such as cIAP2 and SGK1 [50]. 
Furthermore, riborepression appears operative in vivo in response to physiological stress, such as serum 
starvation, which elevates GAS5 lncRNA levels [50]. 
The sequence of GAS5 lncRNA that interacts with the GR DNA binding domain resides within exon 
12-encoded sequence and comprises a hairpin structure that contains two GRE-like sequences, termed 
GRE-1 and GRE-2, which are complementary to each other [50]. Notably, GAS5 lncRNA can also 
interact with other members of the steroid nuclear receptor superfamily members, particularly 3-keto 
steroid receptors, such as the mineralocorticoid receptor, the androgen receptor and progesterone 
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receptor-A, which can bind DNA-activating GREs, but not estrogen receptor α or peroxisome 
proliferator-activated receptor δ [16,50]. Thus, GAS5 lncRNA may riborepress the action of certain other 
steroid hormones in addition to glucocorticoids. 
A recent study has provided more detailed structural information about GAS5 lncRNA/glucocorticoid 
receptor interaction, including the identity of both the bases within the stem-loop HRE mimic (HREM) 
sequence of GAS5 lncRNA and the amino acids within the DNA binding domain of GR that play crucial 
roles [16]. Interestingly, this interaction occurs in a similar manner to which the GR interacts with 
activating DNA GREs [16]. Notably mutation (G549A) of one of the two GC pairs in the GAS5  
lncRNA HREM sequence that are critical for contacting amino acid residues in helix 1 of the GR DNA 
binding domain is sufficient to inhibit the GR/GAS5 lncRNA interaction, GAS5 lncRNA-mediated 
riborepression and the functional effects of GAS5 lncRNA on several different cell types, albeit in a cell 
type-dependent manner [16]. Thus, compared with the wild-type sequence, mutant (G549A) GAS5 
lncRNA is unable to riborepress androgen-mediated induction of several androgen target genes in 
prostate cancer cells, and its ability to induce apoptosis is either abolished (in prostate and breast cancer 
cell lines) or attenuated (lymphoid cell lines) [16]. The latter observations indicate that riborepression may 
constitute the major molecular mechanism of GAS5 lncRNA action in promoting apoptosis in epithelial 
cell types, but additional mechanisms may contribute to this phenomenon in lymphoid cells. 
7.2. miRNA Sponge 
GAS5 lncRNA has recently been identified as a novel target for miR-21, which functions as an 
oncogene in various types of solid tumour and lymphoma [26]. GAS5 lncRNA is negatively regulated 
by miR-21, as are several other tumour suppressor genes, including PTEN, maspin and PDCD4 [26]. 
This regulation forms one arm of a reciprocal feedback loop, since GAS5 lncRNA itself negatively 
regulates miR-21 [26]. Exon 4-derived sequence of GAS5 is thought to contain a miR-21 binding site [26], 
so that GAS5 lncRNA may function as a miRNA sponge; this sequence is also important for the 
reciprocal negative regulation of GAS5 lncRNA by miR-21 [26]. GAS5 lncRNA is without effect on 
either pri- or pre-miR-21, while miR-21 has no effect on GAS5-encoded snoRNAs, indicating that  
post-transcriptional mechanisms underpin this regulatory loop [26], albeit further work is required for 
more detailed understanding. Finally, GAS5 lncRNA and miR-21 levels are negatively correlated in 
xenografts of MCF7 cells overexpressing GAS5 lncRNA, as well as in clinical breast cancer specimens, 
suggesting that this mechanism is of clinical importance [26], albeit the cause and effect relationship of 
the latter observations is unclear. 
7.3. Regulation of Translation 
GAS5 lncRNA has recently been reported to co-precipitate with the eukaryotic translation initiation 
complex in lymphoma cells, suggestive of a possible role in gene translation [46]. Two novel RNA 
binding motifs have been identified in eukaryotic translation initiation factor 4E (eIF4E) which mediate 
this interaction, but the identity of the GAS5 lncRNA interacting sequence is unknown [46]. GAS5 
lncRNA negatively and specifically regulates the translation of the eIF4E downstream target gene,  
c-Myc, without affecting either other target genes (such as Mcl1, survivin or Bcl2) or global protein 
translation. Direct interaction of GAS5 lncRNA with c-Myc RNA is thought to be involved in this 
regulation, possibly inhibiting the entrance of c-Myc into the polysome [46].  
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8. Conclusions and Perspectives—Novel Clinical Translational Opportunities? 
It is clear from the foregoing that GAS5 expression is reduced in multiple tumours and can impact 
patient outcomes. The role of GAS5 lncRNA in promoting both growth arrest and apoptosis is likely to 
constitute the basis of its tumour suppressor gene function. Moreover, decreased levels of GAS5 lncRNA 
are likely to have major implications for the treatment of such cancers, since radiation therapy and many 
chemotherapies usually depend upon the efficient engagement of the apoptotic machinery for their  
action [56,57]. This argument is underscored by the quantitative relationships that exist between GAS5 
lncRNA levels and both patient prognosis and apoptosis induction in preclinical models (see Sections 5 
and 6.2). Indeed, the latter observations indicate that even small reductions in endogenous GAS5 
expression may adversely impact the responses of some cancer cell types to certain death-inducing 
stimuli, including conventional chemotherapeutic agents. Cell lines representative of advanced cancers 
(hormone-independent breast and prostate cancer, for example) often exhibit low levels of GAS5 
expression (relative to untransformed cells or models of early stage disease) [26,48,49] but crucially, 
these retain the ability to respond to ectopic GAS5 lncRNA [48,49]. It therefore follows that the 
restoration of GAS5 lncRNA levels is likely to improve patient outcomes. 
One simple way to achieve this may be to exploit the natural physiological mechanisms that control 
cellular GAS5 levels, through the use of mTOR inhibition (see Section 4), especially since mTOR 
inhibitors, either alone or in combination with other agents, are already in use in the clinic or the subject 
of multiple clinical trials for a range of cancers [58,59]. However, drug resistance can be an issue with 
these agents [58,59], which led us to address the feasibility of their use for modulating GAS5 lncRNA 
levels in a range of preclinical models of breast and prostate cancer, including hormone insensitive 
disease [49,53]. Thus, rapamycin and the rapalogues, everolimus and temsirolimus, were able to both 
enhance GAS5 lncRNA levels and inhibit culture growth in hormone-sensitive cell lines, whereas 
hormone-independent cells showed resistance to these agents as well as to newer generation inhibitors, 
such as combined mTORC1/mTORC2 and dual PI3K/mTOR inhibitors [49,53]. The hormone-insensitive 
cell lines express lower levels of GAS5 lncRNA than the hormone-sensitive cells [49,53] and further 
functional studies have demonstrated that GAS5 lncRNA is itself required for mTOR inhibitor action in 
prostate cancer cells, as is the case in lymphoid cells (Table 2). Thus, while mTOR inhibition may serve 
as a useful strategy to enhance GAS5 lncRNA levels to promote the death of hormone-sensitive breast 
and prostate cells, it is unlikely to be successful in hormone-insensitive disease for which there is a more 
pressing need to develop novel targeted therapies. 
Better understanding of the mechanisms that underlie GAS5 silencing in advanced cancer may assist 
in this regard. As discussed earlier (Section 5), emerging evidence suggests that epigenetic mechanisms 
may be important, and specific targeting of these may offer novel, mTOR inhibitor-independent 
approaches to enhance GAS5 lncRNA levels. An alternative approach may be to use chemotherapeutic 
agents which are independent of GAS5 lncRNA for their action; for example, GAS5 silencing has no 
effect on imatinib-induced cell death in breast cancer cells [49]. While imatinib per se may not be 
suitable for the treatment of breast cancer [60], it is possible that other agents exist which are  
GAS5-independent, and further drug screening is required to identify these. 
Therapeutics aside, there is potential for GAS5 lncRNA to serve as a biomarker both diagnostically 
and for monitoring therapeutic responses, given the correlations between GAS5 levels and  
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clinico-pathological characteristics, that have been reported for several cancers (Table 1). Such 
monitoring may require sampling of body fluids only for the isolation of exosomes, since a preclinical 
study has shown that GAS5 lncRNA is enriched in these cell-derived vesicles, as are several other 
lncRNA molecules [61]. Although the analysis of lncRNA in urinary exosomes has recently revealed 
that GAS5 lncRNA is not a suitable biomarker for distinguishing prostate cancer from benign prostatic 
hyperplasia (unlike lincRNA-p21) [62], further work is required in a wider range of cancers, particularly 
those in which clear correlations exist between cellular GAS5 lncRNA levels and indices of disease 
progression (Table 1). Finally, given the relationships between mTOR inhibition and GAS5 lncRNA 
levels discussed above in prostate, breast and lymphoid cells, GAS5 lncRNA may potentially serve as a 
predictive biomarker for therapies targeting mTOR, to facilitate the selection of patients who are likely 
to achieve maximum benefit from such treatments, given the associated problems of drug resistance. 
Acknowledgments 
Funded by grants from the Breast Cancer Campaign and Prostate Cancer United Kingdom. 
Author Contributions 
Mark Pickard and Gwyn Williams conceived and wrote the manuscript and approved the final document. 
Conflicts of Interest 
The authors declare no conflict of interest. 
References 
1. Kung, J.T.; Colognori, D.; Lee, J.T. Long noncoding RNAs: Past, present, and future. Genetics 
2013, 193, 651–669. 
2. Morris, K.V.; Mattick, J.S. The rise of regulatory RNA. Nat. Rev. Genet. 2014, 15, 423–437. 
3. Wapinski, O.; Chang, H.Y. Long noncoding RNAs and human disease. Trends Cell Biol. 2011, 21, 
354–361. 
4. Hrdlickova, B.; de Almeida, R.C.; Borek, Z.; Withoff, S. Genetic variation in the non-coding 
genome: Involvement of micro-RNAs and long non-coding RNAs in disease. Biochim. Biophys. 
Acta 2014, 1842, 1910–1922. 
5. Schneider, C.; King, R.M.; Philipson, L.A.B. Genes specifically expressed at growth arrest of 
mammalian cells. Cell 1988, 54, 787–793. 
6. Smith, C.M.; Steitz, J.A. Classification of gas5 as a multi-small-nucleolar-RNA (snoRNA) host 
gene and a member of the 5'-terminal oligopyrimidine gene family reveals common features of 
snoRNA host genes. Mol. Cell Biol. 1998, 18, 6897–6909. 
7. Brameier, M.; Herwig, A.; Reinhardt, R.; Walter, L.; Gruber, J. Human box C/D snoRNAs with miRNA 
like functions: Expanding the range of regulatory RNAs. Nucleic Acids Res. 2011, 39, 675–686. 
8. He, X.; Chen, X.; Zhang, X.; Duan, X.; Pan, T.; Hu, Q.; Zhang, Y.; Zhong, F.; Liu, J.; Zhang, H.; 
et al. An Lnc RNA (GAS5)/SnoRNA-derived piRNA induces activation of TRAIL gene by  
site-specifically recruiting MLL/COMPASS-like complexes. Nucleic Acids Res. 2015, 43, 3712–3725. 
Genes 2015, 6 496 
 
 
9. Ensembl Genome Browser. Available online: http://www.ensembl.org/Homo_sapiens/Gene/ 
Summary?g=ENSG00000234741;r=1:173863900-173868882 (accessed on 14May 2015). 
10. Mourtada-Maarabouni, M.; Hedge, V.L.; Kirkham, L.; Farzaneh, F.; Williams, G.T. Growth arrest 
in human T-cells is controlled by the non-coding RNA growth-arrest-specific transcript 5 (GAS5). 
J. Cell Sci. 2008, 121, 939–946. 
11. Mourtada-Maarabouni, M.; Pickard, M.R.; Hedge, V.L.; Farzaneh, F.; Williams, G.T. GAS5,  
a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer. Oncogene 
2009, 28, 195–208. 
12. Ruiz-Orera, J.; Messeguer, X.; Subirana, J.A.; Alba, M.M. Long non-coding RNAs as a source of 
new peptides. Elife 2014, 3, e03523. 
13. Anderson, D.M.; Anderson, K.M.; Chang, C.L.; Makarewich, C.A.; Nelson, B.R.; McAnally, J.R.; 
Kasaragod, P.; Shelton, J.M.; Liou, J.; Bassel-Duby, R.; et al. A micropeptide encoded by a putative 
long noncoding RNA regulates muscle performance. Cell 2015, 160, 595–606. 
14. Coccia, E.M.; Cicala, C.; Charlesworth, A.; Ciccarelli, C.; Rossi, G.B.; Philipson, L.; Sorrentino, V. 
Regulation and expression of a growth arrest-specific gene (gas5) during growth, differentiation, 
and development. Mol. Cell Biol. 1992, 12, 3514–3521. 
15. Raho, G.; Barone, V.; Rossi, D.; Philipson, L.; Sorrentino, V. The gas 5 gene shows four alternative 
splicing patterns without coding for a protein. Gene 2000, 256, 13–17. 
16. Hudson, W.H.; Pickard, M.R.; de Vera, I.M.; Kuiper, E.G.; Mourtada-Maarabouni, M.; Conn, G.L.; 
Kojetin, D.J.; Williams, G.T.; Ortlund, E.A. Conserved sequence-specific lincRNA-steroid  
receptor interactions drive transcriptional repression and direct cell fate. Nat. Commun. 2014, 
doi:10.1038/ncomms6395. 
17. Muller, A.J.; Chatterjee, S.; Teresky, A.; Levine, A.J. The gas5 gene is disrupted by a frameshift 
mutation within its longest open reading frame in several inbred mouse strains and maps to murine 
chromosome 1. Mamm. Genome 1998, 9, 773–774. 
18. Fleming, J.V.; Hay, S.M.; Harries, D.N.; Rees, W.D. Effects of nutrient deprivation and 
differentiation on the expression of growth-arrest genes (gas and gadd) in F9 embryonal carcinoma 
cells. Biochem. J. 1998, 330, 573–579. 
19. Williams, G.T.; Farzaneh, F. Are snoRNAs and snoRNA host genes new players in cancer?  
Nat. Rev. Cancer 2012, 12, 84–88. 
20. Fleming, J.V.; Fontanier, N.; Harries, D.N.; Rees, W.D. The growth arrest genes gas5, gas6, and 
CHOP-10 (gadd153) are expressed in the mouse preimplantation embryo. Mol. Reprod. Dev. 1997, 
48, 310–316. 
21. Vacha, S.J.; Bennett, G.D.; Mackler, S.A.; Koebbe, M.J.; Finnell, R.H. Identification of a growth 
arrest specific (gas 5) gene by differential display as a candidate gene for determining susceptibility 
to hyperthermia-induced exencephaly in mice. Dev. Genet. 1997, 21, 212–222. 
22. Okada, A.; Kushima, K.; Aoki, Y.; Bialer, M.; Fujiwara, M. Identification of early-responsive genes 
correlated to valproic acid-induced neural tube defects in mice. Birth Defects Res. A Clin. Mol. 
Teratol. 2005, 73, 229–238. 
23. Jin, K.; Mao, X.O.; Eshoo, M.W.; del Rio, G.; Rao, R.; Chen, D.; Simon, R.P.; Greenberg, D.A. 
cDNA microarray analysis of changes in gene expression induced by neuronal hypoxia in vitro. 
Neurochem. Res. 2002, 27, 1105–1112. 
Genes 2015, 6 497 
 
 
24. Haywood, M.E.; Rose, S.J.; Horswell, S.; Lees, M.J.; Fu, G.; Walport, M.J.; Morley, B.J. 
Overlapping BXSB congenic intervals, in combination with microarray gene expression, reveal 
novel lupus candidate genes. Genes Immun. 2006, 7, 250–263. 
25. Gee, H.E.; Buffa, F.M.; Camps, C.; Ramachandran, A.; Leek, R.; Taylor, M.; Patil, M.; Sheldon, H.; 
Betts, G.; Homer, J.; et al. The small-nucleolar RNAs commonly used for microRNA normalisation 
correlate with tumour pathology and prognosis. Br. J. Cancer 2011, 104, 1168–1177. 
26. Zhang, Z.; Zhu, Z.; Watabe, K.; Zhang, X.; Bai, C.; Xu, M.; Wu, F.; Mo, Y.Y. Negative regulation 
of lncRNA GAS5 by miR-21. Cell Death Differ. 2013, 20, 1558–1568. 
27. Romanuik, T.L.; Wang, G.; Morozova, O.; Delaney, A.; Marra, M.A.; Sadar, M.D. LNCaP Atlas: 
Gene expression associated with in vivo progression to castration-recurrent prostate cancer.  
BMC Med. Genomics 2010, doi:10.1186/1755-8794-3-43. 
28. Zhang, X.Q.; Sun, S.; Lam, K.F.; Kiang, K.M.; Pu, J.K.; Ho, A.S.; Lui, W.M.; Fung, C.F.;  
Wong, T.S.; Leung, G.K. A long non-coding RNA signature in glioblastoma multiforme predicts 
survival. Neurobiol. Dis. 2013, 58, 123–131. 
29. Qiao, H.P.; Gao, W.S.; Huo, J.X.; Yang, Z.S. Long non-coding RNA GAS5 functions as a tumor 
suppressor in renal cell carcinoma. Asian Pac. J. Cancer Prev. 2013, 14, 1077–1082. 
30. Liu, Z.; Wang, W.; Jiang, J.; Bao, E.; Xu, D.; Zeng, Y.; Tao, L.; Qiu, J. Downregulation of GAS5 
promotes bladder cancer cell proliferation, partly by regulating CDK6. PLoS ONE 2013, 8, e73991. 
31. Tu, Z.Q.; Li, R.J.; Mei, J.Z.; Li, X.H. Down-regulation of long non-coding RNA GAS5 is associated 
with the prognosis of hepatocellular carcinoma. Int. J. Clin. Exp. Pathol. 2014, 7, 4303–4309. 
32. Lu, X.; Fang, Y.; Wang, Z.; Xie, J.; Zhan, Q.; Deng, X.; Chen, H.; Jin, J.; Peng, C., Li, H.; Shen, B. 
Downregulation of gas5 increases pancreatic cancer cell proliferation by regulating CDK6.  
Cell Tissue Res. 2013, 354, 891–896. 
33. Shi, X.; Sun, M.; Liu, H.; Yao, Y.; Kong, R.; Chen, F.; Song, Y. A critical role for the long  
non-coding RNA GAS5 in proliferation and apoptosis in non-small-cell lung cancer. Mol. Carcinog. 
2013, doi:10.1002/mc.22120. 
34. Dong, S.; Qu, X.; Li, W.; Zhong, X.; Li, P.; Yang, S.; Chen, X.; Shao, M.; Zhang, L. The long  
non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase 
inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the  
IGF-1R expression. J. Hematol. Oncol. 2015, doi:10.1186/s13045-015-0140-6. 
35. Renganathan, A.; Kresoja-Rakic, J.; Echeverry, N.; Ziltener, G.; Vrugt, B.; Opitz, I.; Stahel, R.A.; 
Felley-Bosco, E. GAS5 long non-coding RNA in malignant pleural mesothelioma. Mol. Cancer 
2014, doi:10.1186/1476-4598-13-119. 
36. Sun, M.; Jin, F.Y.; Xia, R.; Kong, R.; Li, J.H.; Xu, T.P.; Liu, Y.W.; Zhang, E.B.; Liu, X.H.; De, W. 
Decreased expression of long noncoding RNA GAS5 indicates a poor prognosis and promotes cell 
proliferation in gastric cancer. BMC Cancer 2014, doi:10.1186/1476-4598-13-119. 
37. Liu, Y.; Zhao, J.; Zhang, W.; Gan, J.; Hu, C.; Huang, G.; Zhang, Y. lncRNA GAS5 enhances G1 
cell cycle arrest via binding to YBX1 to regulate p21 expression in stomach cancer. Sci. Rep. 2015, 
doi:10.1038/srep10159. 
38. Yin, D.; He, X.; Zhang, E.; Kong, R.; De, W.; Zhang, Z. Long noncoding RNA GAS5 affects cell 
proliferation and predicts a poor prognosis in patients with colorectal cancer. Med. Oncol. 2014, 
doi:10.1007/s12032-014-0253-8. 
Genes 2015, 6 498 
 
 
39. Cao, S.; Liu, W.; Li, F.; Zhao, W.; Qin, C. Decreased expression of lncRNA GAS5 predicts a poor 
prognosis in cervical cancer. Int. J. Clin. Exp. Pathol. 2014, 7, 6776–6783. 
40. Glover, A.R.; Zhao, J.T.; Ip, J.C.; Lee, J.C.; Robinson, B.G.; Gill, A.J.; Soon, P.S.; Sidhu, S.B. 
Long noncoding RNA profiles of adrenocortical cancer can be used to predict recurrence.  
Endocr. Relat. Cancer 2015, 22, 99–109. 
41. Isin, M.; Ozgur, E.; Cetin, G.; Erten, N.; Aktan, M.; Gezer, U.; Dalay, N. Investigation of circulating 
lncRNAs in B-cell neoplasms. Clin. Chim. Acta 2014, 431, 255–259. 
42. Nakamura, Y.; Takahashi, N.; Kakegawa, E.; Yoshida, K.; Ito, Y.; Kayano, H.; Niitsu, N.; Jinnai, I.; 
Bessho, M. The GAS5 (growth arrest-specific transcript 5) gene fuses to BCL6 as a result of 
t(1;3)(q25;q27) in a patient with B-cell lymphoma. Cancer Genet. Cytogenet. 2008, 182, 144–149. 
43. Klein, I.A.; Resch, W.; Jankovic, M.; Oliveira, T.; Yamane, A.; Nakahashi, H.; di Virgilio, M.; 
Bothmer, A.; Nussenzweig, A.; Robbiani, D.F.; et al. Translocation-capture sequencing reveals the 
extent and nature of chromosomal rearrangements in B lymphocytes. Cell 2011, 147, 95–106. 
44. Kim, H.; Gillis, L.C.; Jarvis, J.D.; Yang, S.; Huang, K.; Der, S.; Barber, D.L. Tyrosine kinase 
chromosomal translocations mediate distinct and overlapping gene regulation events. BMC Cancer 
2011, doi:10.1186/1471-2407-11-528. 
45. Khamas, A.; Ishikawa, T.; Mogushi, K.; Iida, S.; Ishiguro, M.; Tanaka, H.; Uetake, H.; Sugihara, K. 
Genome-wide screening for methylation-silenced genes in colorectal cancer. Int. J. Oncol. 2012, 
41, 490–496. 
46. Hu, G.; Lou, Z.; Gupta, M. The long non-coding RNA GAS5 cooperates with the eukaryotic 
translation initiation factor 4E to regulate c-Myc translation. PLoS ONE 2014, 9, e107016. 
47. Williams, G.T.; Hughes, J.P.; Stoneman, V.; Anderson, C.L.; McCarthy, N.J.; Mourtada-Maarabouni, M.; 
Pickard, M.; Hedge, V.L.; Trayner, I.; Farzaneh, F. Isolation of genes controlling apoptosis through 
their effects on cell survival. Gene Ther. Mol. Biol. 2006, 10, 255–262. 
48. Pickard, M.R.; Mourtada-Maarabouni, M.; Williams, G.T. Long non-coding RNA GAS5 regulates 
apoptosis in prostate cancer cell lines. Biochim. Biophys. Acta 2013, 1832, 1613–1623. 
49. Pickard, M.R.; Williams, G.T. Regulation of apoptosis by long non-coding RNA GAS5 in breast 
cancer cells: Implications for chemotherapy. Breast Cancer Res. Treat. 2014, 145, 359–370. 
50. Kino, T.; Hurt, D.E.; Ichijo, T.; Nader, N.; Chrousos, G.P. Noncoding RNA gas5 is a growth  
arrest- and starvation-associated repressor of the glucocorticoid receptor. Sci. Signal 2010, 
doi:10.1126/scisignal.2000568. 
51. Mourtada-Maarabouni, M.; Hasan, A.M.; Farzaneh, F.; Williams, G.T. Inhibition of human T-cell 
proliferation by mammalian target of rapamycin (mTOR) antagonists requires noncoding RNA 
growth-arrest-specific transcript 5 (GAS5). Mol. Pharmacol. 2010, 78, 19–28. 
52. Mourtada-Maarabouni, M.; Williams, G.T. Role of GAS5 noncoding RNA in mediating the effects 
of rapamycin and its analogues on mantle cell lymphoma cells. Clin. Lymphoma Myeloma Leuk. 
2014, 14, 468–473. 
53. Yacqub-Usman, K.; Pickard, M.R.; Williams, G.T. Reciprocal regulation of GAS5 lncRNA levels 
and mTOR inhibitor action in prostate cancer cells. Prostate 2015, 75, 693–705. 
54. Strasser, A.; Cory, S.; Adams, J.M. Deciphering the rules of programmed cell death to improve 
therapy of cancer and other diseases. EMBO J. 2011, 30, 3667–3683. 
Genes 2015, 6 499 
 
 
55. Tani, H.; Torimura, M.; Akimitsu, N. The RNA degradation pathway regulates the function of 
GAS5 a non-coding RNA in mammalian cells. PLoS ONE 2013, 8, e55684. 
56. McKenzie, S.; Kyprianou, N. Apoptosis evasion: The role of survival pathways in prostate cancer 
progression and therapeutic resistance. J. Cell. Biochem. 2006, 97, 18–32. 
57. Indran, I.R.; Tufo, G.; Pervaiz, S.; Brenner, C. Recent advances in apoptosis, mitochondria and drug 
resistance in cancer cells. Biochim. Biophys. Acta 2011, 1807, 735–745. 
58. Wander, S.A.; Hennessy, B.T.; Slingerland, J.M. Next-generation mTOR inhibitors in clinical 
oncology: How pathway complexity informs therapeutic strategy. J. Clin. Investig. 2011, 121, 
1231–1241. 
59. Zaytseva, Y.Y.; Valentino, J.D.; Gulhati, P.; Evers, B.M. mTOR inhibitors in cancer therapy. 
Cancer Lett. 2012, 319, 1–7. 
60. Yardley, D.A.; Burris, H.A.; Markus, T.; Spigel, D.R.; Greco, F.A.; Mainwaring, M.;  
Waterhouse, D.M.; Webb, C.D.; Hainsworth, J.D. Phase II trial of docetaxal plus imatinib mesylate 
in the treatment of patients with metastatic breast cancer. Clin. Breast Cancer 2009, 9, 237–242. 
61. Gezer, U.; Özgür, E.; Cetinkaya, M.; Isin, M.; Dalay, N. Long non-coding RNAs with low 
expression levels in cells are enriched in secreted exosomes. Cell Biol. Int. 2014, 38, 1076–1079. 
62. Isın, M.; Uysaler, E.; Özgür, E.; Köseoglu, H.; Sanlı, Ö.; Yücel, Ö.B.; Gezer, U.; Dalay, N. 
Exosomal lncRNA-p21 levels may help to distinguish prostate cancer from benign disease.  
Front. Genet. 2015, doi:10.3389/fgene.2015.00168. 
© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/4.0/). 
